ScienceGenmab, AbbVie blood cancer combo cuts progression or death risk in late-stage study
Danish biotech Genmab and U.S. drugmaker AbbVie said their combination treatment for newly diagnosed patients with a type of lymphoma reduced the risk of disease progression or death in a late-stage study.
R
Reuters★★☆☆☆2026-10-05 22:10Original
Genmab, AbbVie blood cancer combo cuts progression or death risk in late-stage study
Science